A study to look at how well emicizumab works when given every 1, 2, or 4 weeks to prevent bleeds in people with mild or moderate haemophilia A without factor 8 inhibitors
A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors
Hemophilia Hemophilia A
For the latest version of this information please go to www.forpatients.roche.com